Oruka Therapeutics SVP sells 1,587 shares

Oruka Therapeutics, Inc. Senior Vice President of Finance Arjun Agarwal reported selling 1,587 shares of Common Stock in open-market transactions.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. Senior Vice President of Finance Arjun Agarwal reported selling 1,587 shares of Common Stock in open-market transactions. The sales occurred at prices of about $82.15 and $80.01 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan entered into on February 11, 2026.

Insider Trade Summary 10b5-1

Net Seller: 1,587 shares

Net Sell 2 txns

Insider Agarwal Arjun

Role Senior Vice President, Finance

Sold 1,587 shs ($128K)

Type	Security	Shares	Price	Value
Sale	Common Stock	888	$80.01	$71K
Sale	Common Stock	699	$82.145	$57K

Holdings After Transaction: Common Stock — 15,312 shares (Direct)

Footnotes (1)

1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

Key Figures

Shares sold total: 1,587 shares First sale size: 699 shares First sale price: $82.145 per share +2 more

5 metrics

Shares sold total 1,587 shares Total Common Stock sold in reported transactions

First sale size 699 shares Common Stock sold on June 22, 2026

First sale price $82.145 per share Price for 699-share sale of Common Stock

Second sale size 888 shares Common Stock sold on June 22, 2026

Second sale price $80.010 per share Price for 888-share sale of Common Stock

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan financial

"These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Oruka Therapeutics (ORKA) disclose in this Form 4?

Oruka Therapeutics disclosed that Senior Vice President of Finance Arjun Agarwal sold 1,587 shares of Common Stock in open-market transactions. The reported sales took place on June 22, 2026 at prices around $80–$82 per share under a trading plan.

How many Oruka Therapeutics (ORKA) shares did the insider sell and at what prices?

The insider sold 1,587 shares of Oruka Therapeutics Common Stock. One block of 699 shares was sold at $82.145 per share, and another 888 shares were sold at $80.010 per share, according to the Form 4 transaction details.

Who is the insider involved in the Oruka Therapeutics (ORKA) Form 4 filing?

The insider is Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics. He is reported as an officer but not a director or 10% owner. The Form 4 lists his trades as direct ownership transactions in the company’s Common Stock.

Were the Oruka Therapeutics (ORKA) insider sales part of a Rule 10b5-1 plan?

Yes. A footnote states the sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. Such plans pre-schedule trades, indicating these sales were planned in advance rather than discretionary timing decisions.

What type of transactions are reported in this Oruka Therapeutics (ORKA) Form 4?

The Form 4 reports two non-derivative transactions coded “S,” meaning open-market or private sales of Common Stock. Both are classified as open-market sales and reduce the insider’s directly owned share position by a net 1,587 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agarwal Arjun

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/22/2026		S(1)		888	D	$80.01	16,011	D
Common Stock	06/22/2026		S(1)		699	D	$82.145	15,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)